Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Second death in Novartis gene therapy trials under investigation

Novartis AG, which previously announced positive interim trial results for the company’s experimental gene therapy for spinal muscular atrophy, said an investigation is underway into whether a second trial death could be related to the treatment.

Read More »

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.

Read More »

Biogen SMA drug price, Novartis estimates for its treatment far too high – U.S. group

Biogen Inc. should slash the price of the spinal muscular atrophy (SMA) drug Spinraza, and the $4 million to $5 million Novartis has said the company’s experimental gene therapy Zolgensma for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said.

Read More »

FDA Approves ADMA’s Asceniv for Immune Deficiency

The U.S. Food and Drug Administration approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents.

Read More »

EU panel approves drug for rare genetic disease

An advisory committee of the EMA recommended conditionally approving a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a rare genetic disease.

Read More »

Roche acquires Spark Therapeutics for $4.3 billion

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.

Read More »

7 Biotech Trends to Look Out for in 2019

Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.

Read More »

Akcea Therapeutics to cut about 10 percent of workforce

Akcea Therapeutics Inc. planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve the company’s Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

Read More »

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. FDA declined to approve a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

Read More »

Vertex cystic fibrosis drug gets expanded approval for use in infants

U.S. health regulators expanded the use of Vertex Pharmaceuticals Inc.’s cystic fibrosis drug Kalydeco to include patients aged between 12 months and 24 months.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom